Your SlideShare is downloading. ×
Avoca quality consortium 2013 initiatives press release
Avoca quality consortium 2013 initiatives press release
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Avoca quality consortium 2013 initiatives press release

193

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
193
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1.              For  Immediate  Release  Media  Contact:             General  Information:  Brittany  Hutt             Caryn  Laermer  Social  Surge  Interactive         Senior  Manager,  Quality  Consortium  Brit@socialsurgeinteractive.com       caryn.laermer@theavocagroup.com  610-­‐212-­‐1230             609-­‐799-­‐0511       Avoca  Quality  Consortium  Announces  2013  Key  Initiatives      Eli  Lilly  &  Co.  and  Pfizer,  Inc.  continue  as  lead  Consortium  sponsors    PRINCETON,  NJ  (January  23,  2013)  –  The  Avoca  Group,  an  industry-­‐leading  consulting  and  research  organization  specializing  in  clinical  outsourcing  and  alliance  management,  announced  today  the  Avoca  Quality  Consortium’s  2013  key  initiatives.    Building  upon  a  successful  launch  year,  the  Avoca  Quality  Consortium  will  implement  additional  initiatives  aimed  at  further  enabling  members  to  optimize  approaches  for  proactive  quality  management  of  outsourced  clinical  trials.    Formed  in  January  of  2012  with  29  members,  The  Avoca  Quality  Consortium  brings  together  executives  from  pharma,  biotech,  and  clinical  research  organizations  (CROs)  to  accelerate  the  development  of  best  practice  approaches  to  quality  management.  Over  the  past  year,  the  Consortium  successfully  completed  the  creation  of  a  Clinical  Quality  Agreement  template  and  a  Quality  Metrics  initiative.      “Our  overarching  goal  is  to  help  our  diverse  members  strike  the  right  balance  between  meeting  timelines,  ensuring  cost  containment  and  achieving  the  highest  level  of  quality  in  their  clinical  trials,”  explained  Patricia  Leuchten,  President  and  CEO  of  Avoca.    “We  made  tremendous  progress  during  our  first  year  and  are  now  poised  to  expand  the  scope  of  this  critically  important  work.”    For  2013,  the  Quality  Consortium  will  conduct  a  consortium-­‐wide  research  assessment  focused  on  managing  risk  in  outsourced  clinical  trials.    This  will  include  an  assessment  of  Consortium  members’  approaches  to  managing  risk  compared  to  the  overall  industry’s  approach.       1  
  • 2. “At  a  time  of  increasing  regulatory  expectations,  industry  collaboration  to  raise  the  bar  on  quality  in  critical  trials  is  more  important  than  ever,  “said  Jeff  Kasher,  Ph.D.,  Vice  President,  Clinical  Trial:  Materials,  Implementation,  and  Transformation,  Eli  Lilly  Co.  “Our  first  year  work  produced  very  practical  tools,  which  many  members  have  already  put  into  use.    Our  2013  focus  on  guidelines  and  tools  for  effective  oversight  will  continue  in  the  same  spirit:  research  that  leads  to  useable  tools  to  support  proactive  quality  management.”    Research  and  work  on  leading  practices  in  proactive  quality  management  serve  as  the  two  pillars  of  the  Avoca  Quality  Consortium.      Members  of  the  Avoca  Quality  Consortium  will  receive  2013  guidelines  and  tools  focused  on  effective  oversight,  revisions  and  refinements  to  its  quality  agreement  and  metrics  tools,  Avoca  research  reports,  participation  in  the  May  Summit  and  Fall  Working  Sessions,  participation  in  regular  WebEx  Meetings  and  updates  on  work  related  to  avenues  for  operationalizing  approaches  to  proactive  quality  management.          Eli  Lilly  &  Company  and  Pfizer,  Inc.  are  founding  corporate  sponsors  and  will  continue  in  that  role  during  2013.  Jeff  Kasher  and  John  Hubbard,  Ph.D.,  FCP,  Senior  Vice  President  and  Worldwide  Head  Development  Operations,  Pfizer,  Inc.  will  co-­‐chair  the  Consortium’s  Annual  Summit  set  for  May  8&9  in  Princeton,  NJ.        For  more  information  about  the  Avoca  Quality  Consortium,  or  to  inquire  about  membership,  please  contact  caryn.laermer@theavocagroup.com    at  (609)  799-­‐0511,  or  visit  the  The  Avoca  Quality  Consortium.             2  

×